Olaparib

Description: Olaparib /AZD-2281/Lynparza is an FDA-approved targeted therapy for cancer including ovarian, breast, and prostate cancers. In January 2018, olaparib became the first PARP inhibitor to be approved by the FDA for gBRCAm metastatic breast cancer.

• Catalog: OFC763113220
• CAS: 763113-22-0
• Category: Fluorinated APIs
• Synonyms: AZD-2281
• Purity: 98%

• IUPAC Name: 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
• InChI: InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
• InChI Key: FDLYAMZZIXQODN-UHFFFAOYSA-N
• Isomeric SMILES: C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
• EC Number: 642-941-5

• Molecular Formula: C24H23FN4O3
• Molecular Weight: 434.46
• Appearance: White solid

• XLogP3-AA: 1.9
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 4
• Exact Mass: 434.17541877 g/mol
• Monoisotopic Mass: 434.17541877 g/mol
• Topological Polar Surface Area: 82.1Ų
• Heavy Atom Count: 32
• Formal Charge: 0
• Complexity: 790